Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cycle 1:~* Patient is scheduled to receive his/her first course of cisplatin chemotherapy at a dose of at least 70 mg/m\^2 administered a maximum of 3 hours~* Patient has a predicted life expectancy of at least 3 months~* Patient is not pregnant~Cycle 2 (optional):~* Participation in the study during the next cycle of chemotherapy is considered~appropriate by the investigator and will not pose unwarranted risk to the patient.~* Satisfactory completion of the preceding cycle of chemotherapy and related~study procedures.~* Patient will continue to receive the same chemotherapy regimen as in Cycle 1. The cisplatin dose may be reduced in subsequent cycle, as long as the new~dose is still no less than 70 mg/m\^2.~Exclusion Criteria:~Cycles 1 \& 2:~* Patient will receive stem cell therapy in conjunction with cisplatin~* Patient has an active infection or any uncontrolled disease (e.g. diabetes)~* Patient will receive multiple-day chemotherapy with cisplatin~* Patient will receive chemotherapy of moderate or high emetogenicity on the 6 days prior to cisplatin infusion or the 6 days following the cisplatin infusion~* Patient has vomited within 24 hours prior to cisplatin infusion~* Patient received or will receive radiation therapy to the abdomen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (MK-0869) (Type: EXPERIMENTAL): None
- Standard Therapy (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).